The therapeutic landscape in oncology has undergone momentous changes in recent years. The treatment options for gastrointestinal (GI) cancers, in particular, have increased with the introduction of novel pharmacological and other treatment modalities. Researchers have gleaned important insights into the molecular biology, pathophysiology and key features of the most prevalent GI cancers, including colorectal, pancreatic and liver. While these advances...